Vol. 5 No. 2 (2025): February
Reimbursement Reviews

Clindamycin Plus Benzoyl Peroxide and Adapalene (Cabtreo)

decorative image of the issue cover

Published February 21, 2025

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Clindamycin 1.2% plus benzoyl peroxide 3.1% and adapalene 0.15% topical gel (Cabtreo).
  • Indication: For the topical treatment of acne vulgaris in patients 12 years of age and older.